source
- Ratio Therapeutics secures $70M Series C for radiopharma trials as Vogenx eyes $67M IPORatio Therapeutics, a Boston-based biotech, announced a $70 million Series C financing to fund its radiopharmaceutical development program. The round was led by existing backers Duquesne Family Of…
- FDA advisory panel backs experimental Replimune melanoma therapy after two prior rejectionsAn FDA advisory committee voted 10‑to‑3 to recommend the use of an experimental Replimune treatment for patients with advanced melanoma. The panel’s recommendation marks a shift after the agency p…